Bayesian quantitative disease-drug-trial models for Parkinson's disease to guide early drug development

AAPS Journal

Volumn 13, Issue 4, 2011, Pages 508-518

  Lee, Joo Yeon ^a   Gobburu, Jogarao V S ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Bayesian method; drug development; prior knowledge; quantitative disease drug trial model

Indexed keywords

BIOLOGICAL MARKER; CARBIDOPA; LEVODOPA; PLACEBO; RASAGILINE;

ALZHEIMER DISEASE; ARTICLE; BAYES THEOREM; BRADYKINESIA; DISEASE COURSE; DISEASE MODEL; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG INFORMATION; DRUG LEGISLATION; DRUG RESEARCH; DRUG RESPONSE; HUMAN; KNOWLEDGE; MATHEMATICAL ANALYSIS; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; METHODOLOGY; PARKINSON DISEASE; PHARMACODYNAMICS; PHARMACOKINETICS; PLACEBO EFFECT; PRACTICE GUIDELINE; PROBABILITY; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS; SYMPTOM;

BAYES THEOREM; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; MODELS, THEORETICAL; PARKINSON DISEASE; RESEARCH DESIGN;

EID: 83555166115     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-011-9293-6     Document Type: Article

References (35)

1. T Elias M Gordian N Singh R Zemmel 2006 Why products fail in phase III In Vivo 24 49 54
2. Hooper M, Amsterdam JD. Do clinical trials reflect drug potential? A review of FDA evaluation of new antidepressants. Presented at NCDEU 39th Annual Meeting, Boca Raton, FL. 11-14 June, 1998.
3. VA Bhattaram BP Booth RP Ramchandani BN Beasley Y Wang V Tandon, et al. 2005 Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications AAPS J 7 E503 E512 16353928 10.1208/aapsj070351 (Pubitemid 41574302)
4. VA Bhattaram C Bonapace DM Chilukuri JZ Duan C Garnett JV Gobburu, et al. 2007 Impact of pharmacometric reviews on new drug approval and labeling decisions-a survey of 31 new drug applications submitted between 2005 and 2006 Clin Pharmacol Ther 81 213 21 17259946 10.1038/sj.clpt.6100051 1:STN:280:DC%2BD2s%2FlsFersA%3D%3D (Pubitemid 46174818)
5. J Gobburu 2008 Disease model Clin Adv Hematol Oncol 6 241 42 18496490
6. J Gobburu LJ Lesko 2009 Quantitative disease, drug and trial models Annu Rev Pharmacol Toxicol 49 291 301 18851702 10.1146/annurev.pharmtox.011008.145613 1:CAS:528:DC%2BD1MXisV2jsb8%3D
7. L Zhang V Sinha ST Forgue S Callies L Ni R Peck, et al. 2006 Model-based drug development: the road to quantitative pharmacology J PKPD 33 3 369 393 1:CAS:528:DC%2BD28XhtlWjtrrJ (Pubitemid 44020386)
8. VA Bhattaram O Siddiqui L Kapcala J Gobburu 2009 Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease AAPS J 11 456 64 19521783 10.1208/s12248-009-9123-2 1:CAS:528:DC%2BD1MXhsFGmur7M
9. J Ibrahim M Chen 2000 Power prior distributions for regression models Stat Sci 15 46 60 10.1214/ss/1009212673
10. NH Holford KE Peace 1992 Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine Proc Natl Acad Sci USA 89 11466 70 1454835 10.1073/pnas.89.23.11466 1:CAS:528:DyaK3sXntlGgsQ%3D%3D
11. PL Chan NH Holford 2001 Drug treatment effects on disease progression Annu Rev Pharmacol Toxicol 41 625 59 11264471 10.1146/annurev.pharmtox.41.1.625 1:CAS:528:DC%2BD3MXjsVaqt7s%3D (Pubitemid 32385901)
12. NH Holford PL Chan JG Nutt K Kieburtz I Shoulson 2006 Disease progression and pharmacodynamics in Parkinson disease-evidence for functional protection with levodopa and other treatments J Pharmacokinet Pharmacodyn 33 281 311 16625427 10.1007/s10928-006-9012-6 1:CAS:528:DC%2BD28Xms1Oisr0%3D (Pubitemid 44020383)
13. Parkinson Study Group 2004 Levodopa and the progression of Parkinson's disease NEJM 351 2498 508 10.1056/NEJMoa033447 (Pubitemid 39603163)
14. Parkinson Study Group 2002 A controlled trial of rasagiline in early Parkinson disease: the TEMPO study Arch Neurol. 59 12 1937 43 10.1001/archneur.59.12.1937 (Pubitemid 35424653)
15. P Guimaraes K Kieburtz CG Goetz J Elm Y Palesch P Huang, et al. 2005 Nonlinearity of Parkinson's disease progression: implication for sample size calculation in clinical trials Clin Trials 2 509 18 16422311 10.1191/1740774505cn125oa (Pubitemid 43075658)
16. A Gelman DB Rubin 1992 Inference from iterative simulation using multiple sequences (with discussion) Stat Sci 7 457 511 10.1214/ss/1177011136
17. Gelman A, Carlin J, Stern H, Rubin D. Bayesian data analysis. 1st ed. London: Chapman & Hall/CRC; 1995.
18. JC Wakefield 1996 The Bayesian analysis of population pharmacokinetic models J Am Stat Ass 91 61 76
19. JC Wakefield 1996 Bayesian individualisation via sampling-based methods J Pharmacokinet Biopharm 24 103 131 8827585 10.1007/BF02353512 1:STN:280:DyaK28visFWgtg%3D%3D (Pubitemid 26253195)
20. DJ Spiegelhalter L Freedman MKB Parmar 1994 Bayesian approaches to randomized clinical trials (with discussion) J Roy Stat Soc Ser A 157 357 415 10.2307/2983527
21. Gilks WR, Richardson S, Spiegelhalter DJ. Markov Chain Monte Carlo in practice. London: Chapman and Hall; 1996.
22. Chaloner K. Elicitation of prior distributions. In: Berry DA, Stangl DK, editors. Bayesian biostatistics. New York: Marcel Dekker; 1996. p. 141-56.
23. K Chaloner FS Rhame 2001 Quantifying and documenting prior beliefs in clinical trials Stat Med 20 581 600 11223902 10.1002/sim.694 1:STN:280:DC%2BD3M3isF2jsA%3D%3D (Pubitemid 32166421)
24. JB Kadange LJ Wolfson 1998 Experiences in elicitation The Statistician. 47 3 19 10.1111/1467-9884.00113 (Pubitemid 128469059)
25. A O'Hagan 1998 Eliciting expert beliefs in substantial practical applications The Statistician 47 21 35 10.1111/1467-9884.00114 (Pubitemid 128469060)
26. Press SJ. Subjective and objective Bayesian statistics. 2nd ed. New Jersey: Wiley; 2003.
27. M Chen J Ibrahim 2006 The relationship between the power prior and hierarchical models Bayesian Anal 1 551 74 10.1214/06-BA118
28. H Chen J Ibrahim Q Shao RE Weiss 2003 Prior elicitation for model selection and estimation in generalzied linear mixed models J Stat Plan Inf 111 57 76 10.1016/S0378-3758(02)00285-9
29. B Neelon AJ O'Malley 2010 Bayesian analysis using power priors with application to pediatric quality of care J Biomet Biostat 1 1 9 10.4172/2155-6180.1000103
30. A Gelman A Meng H Stern 1996 Posterior predictive assessment of model fitness via realized discrepancies Stat Sin 6 733 807 (Pubitemid 126706389)
31. X Meng 1994 Posterior predicitve p values Ann Stat 22 1142 1160 10.1214/aos/1176325622
32. Little RJA, Rubin DB. Statistical analysis with missing data. 2nd ed. New Jersey: Wiley; 2002.
33. P Diggle MG Kenward 1994 Informative drop-out in longitudinal data analysis Applied Statistics 43 49 73 10.2307/2986113
34. RJA Little 1995 Modeling the drop-out mechanism in repeated-measures studies J Am Stat Assoc 90 1112 1121 10.2307/2291350
35. NONMEM: nonlinear-mixed effects modelling, Icon Development Solutions, Ellicot City, MD, USA.